Emyria Ltd (ASX:EMD)'s Michael Winlo tells Proactive's Andrew Scott they've contracted a leading North American drug manufacturer to deliver a range of novel, synthetic cannabinoid-based (CBD) medicines for its Australian and US drug registration program. They've engaged Altasciences, an award-winning contract drug manufacturer with more than 1,000 employees and seven locations across the US and Canada, to deliver a range of proprietary, synthetic cannabinoid-based capsules utilising a unique drug delivery approach.
Emyria to accelerate FDA and TGA CBD registration programs with Altasciences deal
Quick facts: Emyria Ltd
Price: 0.235 AUD
Market Cap: $59.71 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE